- Home
- GILD vs UBS Comparison
GILD vs UBS Comparison
Compare GILD & UBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GILD | UBS |
|---|---|---|
| Founded | 1987 | 1862 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 128.4B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GILD | UBS |
|---|---|---|
| Price | $144.37 | $36.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 2 |
| Target Price | ★ $146.50 | $60.30 |
| AVG Volume (30 Days) | ★ 5.5M | 2.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.26% | 1.47% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.68 | $8.07 |
| Revenue Next Year | $6.10 | $3.47 |
| P/E Ratio | $21.44 | ★ $17.22 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $95.30 | $25.75 |
| 52 Week High | $157.29 | $49.36 |
Technical Indicators
Market Signals| Indicator | GILD | UBS |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 22.52 |
| Support Level | $142.93 | $36.19 |
| Resistance Level | $157.29 | $38.81 |
| Average True Range (ATR) | 3.21 | 0.77 |
| MACD | -1.06 | -0.21 |
| Stochastic Oscillator | 27.44 | 0.39 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.